Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Form 8.5 (EPT/NON-RI)

9 Apr 2025 10:45

RNS Number : 3243E
Cavendish Securities PLC
09 April 2025
 

FORM 8.5 (EPT/NON-RI)

 

 

 

 

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cavendish Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Tissue Regenix Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Tissue Regenix Group Plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

08/04/2025

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

ORD 0.1P

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

61021

 

 

0.09

 

 

 

 

 

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

61021

 

 

 

0.09

 

 

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

ORD 0.1P

 

 

 

 

 

 

 

 

Sale

15129

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

38.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

35.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

09/04/2025

Contact name:

Nancy Dyer

Telephone number:

0207 220 0594

 

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEOUKSKRVSUSRRR
Date   Source Headline
24th May 201812:12 pmRNSResult of AGM
2nd May 20187:00 amRNSTRX BioSurgery GPO agreement with Premier, Inc.
27th Apr 20187:00 amRNSPosting of Annual Report and Notice of AGM
24th Apr 20187:00 amRNSDermaPure manufacturing at CellRight Facility
19th Apr 20183:29 pmRNSHolding(s) in Company
5th Apr 20187:17 amEQSHardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note
26th Mar 20187:00 amRNSAnnual results for period ended 31 December 2017
16th Mar 20183:40 pmRNSPublication of Financial Results
8th Mar 20187:15 amRNSHardman & Co: Full-year 2017 - what to look for
6th Mar 20187:00 amRNSLong term distribution agreement with Arthrex, Inc
26th Feb 20187:00 amRNSNotice of Results
26th Feb 20187:00 amRNSLaunch of BioSurgery and new distributor agreement
2nd Feb 20187:00 amRNSIssue of Equity
22nd Dec 20179:30 amRNSIssue of Equity
1st Dec 20177:00 amRNSDirectorate Change
1st Dec 20177:00 amRNSIssue of Equity
2nd Nov 20177:00 amRNSAppointment of CEO
18th Oct 20177:00 amRNSDirectorate Change
11th Oct 20177:15 amRNSHardman Research: Dual revenue stream growth
28th Sep 20173:15 pmRNSUnaudited Interim Results
8th Sep 20177:00 amRNSNotice of Results
5th Sep 20173:52 pmRNSNotification Of Major Holdings
30th Aug 20175:15 pmRNSIssue of Equity
16th Aug 201712:22 pmRNSHolding(s) in Company
11th Aug 20173:45 pmRNSHolding(s) in Company
11th Aug 20173:37 pmRNSHolding(s) in Company
10th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20172:45 pmRNSHolding(s) in Company
10th Aug 20171:10 pmRNSHardman Research: CellRight transforming US growth
10th Aug 201710:10 amRNSHolding(s) in Company
9th Aug 20173:00 pmRNSHolding(s) in Company
9th Aug 20172:30 pmRNSDirector/PDMR Shareholding
8th Aug 20171:41 pmRNSResults of General Meeting and Total Voting Rights
21st Jul 20176:00 pmRNSCirc re.CellRight Acquisition
21st Jul 20178:05 amRNSSuccessful fundraising of £40 million
20th Jul 20176:03 pmRNSProposed Acquisition and Placing
30th Jun 201712:00 pmRNSResult of AGM
2nd Jun 20177:00 amRNSAnnual results for period ended 31 December 2016
31st May 201710:46 amRNSPotential Acquisition Update
19th May 201711:35 amRNSPotential Acquisition
3rd Apr 20177:00 amRNSIssue of Equity
13th Mar 20177:10 amRNSHardman Research: Addressing woundcare in the US
1st Mar 20177:00 amRNSInnovative Technology Contract Awarded
2nd Feb 20177:00 amRNSDermaPure® added to the Federal Supply Schedule
6th Jan 20177:00 amRNSDirectorate Change
9th Dec 20167:15 amRNSHardman Research: a/c change: Not simply 11/12ths
7th Dec 20161:04 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Dec 20167:00 amRNSDermaPure secures GPO agreement with Premier, Inc.
28th Nov 20167:05 amRNSOrthoPureT XT update
22nd Nov 20167:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.